Molecular structure of VX 745, CAS Number: 209410-46-8
VX 745 (CAS 209410-46-8)
See product citations (4)
Alternate Names:
5-(2,6-Dichlorophenyl)-2-[2,4-difluorophenyl)thio]-6H-pyrimido[1,6-b]pyridazin-6-one
Application:
VX 745 is a selective and highly potent p38α and p38β inhibitor
CAS Number:
209410-46-8
Purity:
≥96%
Molecular Weight:
436.26
Molecular Formula:
C19H9Cl2F2N3OS
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
VX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38α, p38βand p38γ. VX-745 is a p38 MAP kinase inhibitor, which means that it works by inhibiting the activity of the p38 MAP kinase enzyme. This enzyme is involved in a variety of cellular processes, including inflammation, cell growth, and apoptosis. By inhibiting the activity of this enzyme, neflamapimod is able to reduce inflammation, cell growth, and apoptosis.
VX 745 (CAS 209410-46-8) References
- Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. | Hideshima, T., et al. 2003. Blood. 101: 703-5. PMID: 12393542
- P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes. | Natarajan, SR. and Doherty, JB. 2005. Curr Top Med Chem. 5: 987-1003. PMID: 16178742
- Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells. | Bagley, MC., et al. 2007. Bioorg Med Chem Lett. 17: 5107-10. PMID: 17659871
- P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. | Brown, KK., et al. 2008. J Inflamm (Lond). 5: 22. PMID: 19055838
- Microwave-assisted Ullmann C-S bond formation: synthesis of the P38alpha MAPK clinical candidate VX-745. | Bagley, MC., et al. 2009. J Org Chem. 74: 8336-42. PMID: 19778055
- Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome. | Bagley, MC., et al. 2010. Future Med Chem. 2: 1417-27. PMID: 21426137
- The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor. | Duffy, JP., et al. 2011. ACS Med Chem Lett. 2: 758-63. PMID: 24900264
- Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release system. | Pradal, J., et al. 2015. Eur J Pharm Biopharm. 93: 110-7. PMID: 25836052
- Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats. | Alam, JJ. 2015. J Alzheimers Dis. 48: 219-27. PMID: 26401942
- Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome. | Bagley, MC., et al. 2010. Pharmaceuticals (Basel). 3: 1842-1872. PMID: 27713332
- Activating β-catenin/Pax6 axis negatively regulates osteoclastogenesis by selectively inhibiting phosphorylation of p38/MAPK. | Jie, Z., et al. 2019. FASEB J. 33: 4236-4247. PMID: 30526042
- Pharmacological inhibition of p38 potentiates antimicrobial peptide TP4-induced cell death in glioblastoma cells. | Su, BC. and Chen, JY. 2020. Mol Cell Biochem. 464: 1-9. PMID: 31673920
- P38α-MAPK Signaling Inhibition Attenuates Soleus Atrophy during Early Stages of Muscle Unloading. | Belova, SP., et al. 2020. Int J Mol Sci. 21: PMID: 32326654
- The role of MAP-kinase p38 in the m. soleus slow myosin mRNA transcription regulation during short-term functional unloading. | Sharlo, KA., et al. 2020. Arch Biochem Biophys. 695: 108622. PMID: 33053365
- Pleckstrin Levels Are Increased in Patients with Chronic Periodontitis and Regulated via the MAP Kinase-p38α Signaling Pathway in Gingival Fibroblasts. | Alim, MA., et al. 2021. Front Immunol. 12: 801096. PMID: 35087525
Inhibitor of:
ARK5, BTEB1, BTNL10, Btnl6, Btnl7, C030010C08Rik, C030014O09Rik, C030017K20Rik, C030019I05Rik, C030030A07Rik, C030034I22Rik, C030048H21Rik, C130074G19Rik, C130079G13Rik, C6orf150, CNK2, Cytokeratin 12, DUSP22, hPAK p65, IDE, IFN-α13, IL-14, KIAA0701, MAPK15, MAPKBP-1, MEK-3, MEK3, Mkk2, MKS1, Mxi 2, Olfr462, Olfr520, Olfr521, OTTMUSG00000011262, OTTMUSG00000011265, p38, p38 alpha, p38γ MAPK12, Pbs2, RAG-1, RELL2, Ser/Thr Protein Kinase, Sprouty 4, T2BP, TAGAP1, Taok3, TMEM232, Trav7-1, TREML6, TSSK 1, TSSK 6, and Vmn2r39.Activator of:
ADAM6A, ADAM6B, AMPA 2, BAZ1A, BC057022, DUSP23, MINK1, MSK1, and Tak1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
VX 745, 10 mg | sc-361401 | 10 mg | $183.00 | |||
VX 745, 50 mg | sc-361401A | 50 mg | $842.00 |